Emmaus Life Sciences ( (EMMA) ) has released a notification of late filing.
Emmaus Life Sciences, Inc. has announced a delay in filing its Form 10-K (Yearly Report) for the financial period ending December 31, 2024. The primary reason for the delay is the need for additional time to complete the first audit of annual financial statements by a newly retained independent accounting firm. The company expects to file the report within 15 calendar days following the original due date. Financially, Emmaus anticipates a significant decline in net revenues by more than $12 million, or over 40%, compared to 2023, primarily due to a lack of finished goods inventory in the first half of 2024. However, this is expected to be partially offset by a reduction in operating expenses. The company is committed to compliance efforts, as indicated by the signature of Yasushi Nagasaki, Chief Financial Officer, on the notification.
More about Emmaus Life Sciences
YTD Price Performance: 70.0%
Average Trading Volume: 47,003
Technical Sentiment Signal: Buy
Current Market Cap: $1.09M
For an in-depth examination of EMMA stock, go to TipRanks’ Stock Analysis page.